Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$589.99 USD

589.99
691,572

+4.25 (0.73%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?

by Zacks Equity Research

Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

by Zacks Equity Research

In terms of performance in high-growth and emerging markets, in its flagship facility for cell culture media in Grand Island, NY, Thermo Fisher (TMO) completes capacity expansion.

3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

LabCorp (LH) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

LabCorp's (LH) growth in early development and clinical development are expected to have been offset by central labs on the account of a significant slowdown in COVID-related work.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q3 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ

by Zacks Equity Research

Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.

Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.

Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Accuray's (ARAY) New Treatment Package to Boost Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.

What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?

by Zacks Equity Research

Going by the industry-wide trend so far, logistical challenges and increasing unit costs might have weighed on the corporate profitability of Abbott (ABT) in Q3.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns

by Zacks Equity Research

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Thermo Fisher (TMO) Launches New TaqPath Panel in Europe

by Zacks Equity Research

This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.

Charles River's (CRL) New Launch to Boost Gene Therapy Workflow

by Zacks Equity Research

Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.

Snehadri Nag headshot

4 Defensive Bets to Pacify Pessimists to Ride Market Storms

by Snehadri Nag

Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water, McKesson and Hershey with strong prospects to stay afloat in the bear market.

3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.

McKesson (MCK) Stock Moves -1.2%: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed at $346.68 in the latest trading session, marking a -1.2% move from the prior day.

Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues

by Zacks Equity Research

Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips

by Zacks Equity Research

Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.